Joseph Goldberg
Psychiatry · New Canaan, CTNPI 1194948323
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $622,111 of the $914,439 with a category attached, or 68.0%. 16 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 33.7% of the total. 2025 is the largest year on record at $289,341, 3.4 times the $86,102 reported in 2019. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 904 payments — averaging $1011.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$308K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$145K
- Alkermes, Inc.$118K
- E.r. Squibb & Sons, L.L.C.$104K
- Axsome Therapeutics, Inc.$82K
- AbbVie$79K
- plus $80K from 10 others
Across 1 payment — averaging $900.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$900
What the payments were for
- Consulting fees$194,75521%
- Speaking & faculty fees$622,11168%
- Travel & lodging$77,9449%
- Food & beverage$19,6292%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 268 | $308,337 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 138 | $144,759 |
| Alkermes, Inc. | 108 | $117,741 |
| E.r. Squibb & Sons, L.L.C. | 76 | $103,519 |
| Axsome Therapeutics, Inc. | 70 | $81,707 |
| AbbVie(2 entities) | 162 | $78,687 |
| Otsuka America Pharmaceutical, Inc. | 23 | $23,269 |
| Sunovion Pharmaceuticals Inc. | 33 | $23,010 |
| Vanda Pharmaceuticals Inc. | 11 | $15,334 |
| Neurelis, Inc. | 1 | $4,554 |
| H. Lundbeck A S | 2 | $4,500 |
| Merck | 1 | $4,185 |
| Supernus Pharmaceuticals, Inc. | 2 | $1,548 |
| Jazz Pharmaceuticals Inc. | 1 | $1,400 |
| Almatica Pharma LLC | 3 | $1,250 |
| Neurocrine Biosciences, Inc. | 5 | $640 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$464,864
- CAPLYTA$305,162
- Auvelity$80,190
- VRAYLAR$74,254
- COBENFY$72,300
- ABILIFY MAINTENA$21,878
- LATUDA$18,033
- Fanapt$15,153
- ABILIFY ASIMTUFII$10,017
- OSMOLEX ER$1,500
- SUNOSI$1,400
- LOREEV XR$1,250
- INGREZZA$554
How this compares
$914,439 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $88,083 |
| NuplazidPimavanserin Tartrate | 13 | $64,117 |
| VyvanseLisdexamfetamine Dimesylate | 55 | $23,476 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $20,979 |
| VraylarCariprazine Hcl | 11 | $14,961 |
| Lisdexamfetamine Dimesylate | 15 | $13,356 |
| Olanzapine | 29 | $5,283 |
| Vilazodone Hcl | 47 | $4,321 |
| Quetiapine Fumarate | 46 | $2,677 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 31 | $1,845 |
| Mirtazapine | 65 | $1,676 |
| Bupropion XlBupropion Hcl | 65 | $1,675 |
| Armodafinil | 20 | $1,670 |
| Lamotrigine | 79 | $1,499 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 46 | $1,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $640 | $88,08311 claims |
| Axsome Therapeutics, Inc.Auvelity | $81,707 | $20,97914 claims |
| AbbVieVraylar | $78,687 | $14,96111 claims |
| Almatica Pharma LLCSertraline Hcl | $1,250 | $49230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in New Canaan
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
- David MatuskeyFarmington$120K
- Alexia CortellaNewtown$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.